Insider at Medical Device Maker Buys More Than 7,500 Shares
Key Points
The acquisition involved 7,598 shares at a weighted average price of $19.74 per share, representing a total investment of ~$150,000.
The transaction size equals 14% of the equity stake held by the executive before the filing.
This purchase increased total direct holdings to 61,238 shares, with no reported indirect ownership.
The capital commitment occurred following a -37% one-year total return for the stock as of the September 3, 2026 transaction date.
- 10 stocks we like better than Enovis ›
Oliver Engert, Chief Administrative Officer of Enovis Corporation (NYSE:ENOV), executed a direct purchase of 7,598 shares of common stock in transactions on Sept. 2, 2026, and Sept. 3, 2026, according to a recent SEC Form 4 filing.
Transaction summary
| Metric | Value |
|---|---|
| Transaction value | ~$150,000 |
| Shares purchased | 7,598 |
| Post-transaction shares (directly held) | 61,238 |
| Post-transaction value | ~$1.19 million |
Transaction value based on SEC Form 4 weighted average purchase price ($19.74); post-transaction value based on Sept. 3, 2026 market close ($19.40).
Key questions
- How does the acquisition price compare to current market levels?
Oliver Engert executed the purchase at a weighted average price of $19.74 per share, while the stock was priced at $18.56 as of the Sept. 4, 2026 market close. - What is the scale of the insider's total equity position following this move?
The addition of 7,598 shares brings the total direct holding to 61,238 shares, representing an ownership stake of 0.11% in the $1.1 billion medical technology enterprise. - What pricing ranges were reported for this acquisition?
According to regulatory footnotes, the shares were acquired in multiple transactions at price ranges of $19.33 to $19.75 and $20.145 to $20.50, respectively. - What are the current financial fundamentals reported by the company?
Enovis Corporation reported trailing twelve-month revenue of $2.3 billion and a net loss of $1.1 billion as of the most recent reporting period.
Company Overview
| Metric | Value |
|---|---|
| Share Price (as of market close 2026-09-04) | $18.56 |
| Market Capitalization | $1.1 billion |
| Revenue (TTM) | $2.3 billion |
| Net Income (TTM) | -$1.1 billion |
Company Snapshot
- Enovis Corporation designs, manufactures, and distributes specialized medical devices for the treatment of musculoskeletal conditions, serving orthopedic specialists, surgeons, pain management experts, physical therapists, and other healthcare professionals across global markets.
- The company generates revenue through the sale of innovative medical device solutions that address degenerative illnesses, deformities, and traumatic injuries, leveraging a diversified product portfolio across orthopedic and musculoskeletal care segments.
- Enovis serves a broad customer base, including orthopedic surgeons, general physicians, pain management specialists, physical therapists, podiatrists, chiropractors, and athletic trainers who treat patients requiring musculoskeletal interventions and rehabilitation solutions.
Enovis Corporation is a global medical technology enterprise with approximately 7,802 employees and TTM revenues of $2.3 billion, positioning it as a significant player in the medical devices sector focused on musculoskeletal health solutions. The company operates across multiple therapeutic areas and geographic markets, serving healthcare professionals who treat patients with complex orthopedic and musculoskeletal conditions. Despite current profitability challenges reflected in TTM net losses, Enovis maintains a substantial revenue base and market presence in the specialized medical device industry.
What this transaction means for investors
Not all insider transactions have the same impact. Some are executed for tax purposes; others are done for estate planning. However, insider buys send a more clear message. They signal that an insider believes the company's stock is undervalued and is willing to put their own money on the line. Nonetheless, retail investors shouldn't blindly buy simply because insiders are. Instead, investors should review a company's fundamentals. With that in mind, let's have a look at Enovis (ENOV).
First off, let's take a look at how ENOV stock has performed. Since 2021, the company's shares have generated a total return of -76%, equating to a compound annual growth rate (CAGR) of -24.9%. The S&P 500, meanwhile, has delivered an 83% total return, with a 12.9% CAGR over the same period.
Turning to its core fundamentals, ENOV paints a mixed picture. On the one hand, free cash flow has increased significantly in recent years. After hitting a multi-year low of $(150) million in 2023, free cash flow has risen to $64 million now. In addition, revenue has climbed to $2.3 billion, up from $1.5 billion in 2022.
However, concerns remain. Profitability is a big one. ENOV continues to record net losses. The company's net loss over the last 12 months stands at $(1.1) billion. Moreover, net debt stands at $1.36 billion, presenting a significant hurdle for the stock.
All in all, the recent insider buys provide confidence that management sees brighter days ahead. In addition, the company's improving free cash flow lends credibility to this thesis. However, several key metrics, such as net debt and ongoing net losses, indicate that ENOV still faces challenges.
Should you buy stock in Enovis right now?
Before you buy stock in Enovis, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Enovis wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $417,413!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,341,294!*
Now, it’s worth noting Stock Advisor’s total average return is 950% — a market-crushing outperformance compared to 212% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of September 14, 2026.
Jake Lerch has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Recommended Articles
